APOA4 and fetal growth restriction: The above findings indicate the intricate connection between the expression of APOA4 during IUGR and the PPAR signaling pathway, highlighting the considerable potential of APOA4 as both a therapeutic target and a biomarker for IUGR‐induced liver damage.